echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Science journal: Zhejiang University Zhou Min's team uses spirulina as a drug delivery vehicle for the treatment of colon cancer and colitis

    Science journal: Zhejiang University Zhou Min's team uses spirulina as a drug delivery vehicle for the treatment of colon cancer and colitis

    • Last Update: 2021-12-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Written | Edited by Wang Cong | Typeset by Wang Duoyu | Oral administration in water is the first and most commonly used route of administration for the treatment of gastrointestinal diseases, mainly due to its high safety, high patient compliance, convenience and ease of production, etc.
    Advantage

    .

    However, oral administration still has many challenges.
    For example, the active ingredients of the drug are degraded in the acidic environment of the stomach, resulting in poor retention and low bioavailability in the intestinal tract

    .

    In order to improve the efficacy of oral administration, researchers have designed a variety of drug carriers for oral administration systems, such as: liposomes, dendrimers, micelles, polymer conjugates, polymer nanoparticles, silicon or carbon material and a metal magnetic nanoparticles and the like
    .

    Generally, these candidate drug carriers achieve their complex functions through complex design, synthesis, and construction processes, and optimize their physical and chemical properties, so that they can be used for drug delivery and therapeutic diagnostic applications
    .

    However, these carriers face many important problems, such as the technical challenges brought about by the complex synthesis process, high cost and low efficiency
    .

    In addition, these artificially synthesized substances have to face severe limitations such as low biodegradability, poor stability, and potential toxicity in clinical applications
    .

    Therefore, it is very necessary to develop a simple, versatile, and biocompatible drug delivery strategy
    .

    On November 24, 2021, Zhou Min's team from the Second Affiliated Hospital of Zhejiang University School of Medicine/Institute of Translational Medicine and Tao Wei's team from Harvard Medical School published the title: Orally deliverable strategy based on microalgal biomass for intestinal in Science Advances.
    Research papers on disease treatment

    .

    This paper is also the cover paper of the current issue
    .

    The study used Spirulina platensis, a natural active microalgae, as a drug carrier for curcumin, and constructed a drug delivery system for the treatment of colon cancer and colitis, two intestinal diseases-SP@Curcumin, in the intestines It also shows excellent anti-tumor and anti-inflammatory effects in the treatment of tract diseases
    .

    In the radiotherapy of colon cancer, SP@Curcumin can be combined with chemotherapy and radiotherapy to inhibit tumor progression, and at the same time as a radioprotective agent to eliminate high-dose X-ray radiation-induced reactive oxygen species (ROS) in healthy tissues, thereby reducing DNA damage
    .

    SP@Curcumin can also reduce the production of pro-inflammatory cytokines, thereby exerting an anti-inflammatory effect on colitis
    .

    As a kind of natural microalgae, spirulina has extremely high nutritional value and good biological safety, and can be made into a nutritional supplement for the human body
    .

    Not only that, the negatively charged surface of Spirulina can be loaded with positively charged small molecule drugs through electrostatic adsorption.
    The water channels and connection pores on the cell membrane also allow small molecules to pass through and enter its membrane, so it is more effective for drugs.
    High load efficiency

    .

    In addition, the natural chlorophyll in Spirulina has fluorescent properties, so it can achieve non-invasive tracking in vivo without any additional fluorescent labels
    .

    Curcumin is the active ingredient of Curcuma longa (Curcuma longa L.
    ) in the ginger family

    .
    It
    has a medicinal history for hundreds of years in China .

    Recent studies have shown that curcumin has antioxidant effects, can fight inflammation and rebuild bones, and studies have shown that it can prevent various cancers
    .

    Moreover, curcumin has also been approved for use by the US FDA
    .

    In this study, spirulina was loaded with curcumin (SP@Curcumin), which can pass through the stomach intact while keeping the structure intact, and then be captured by the intestinal villi and gradually degrade and release curcumin in the intestinal tract.
    Realize ideal drug distribution without causing adverse reactions

    .

    In the traditional radiotherapy model of colon cancer, SP@Curcumin uses a combination of chemotherapy and radiotherapy to inhibit tumor progression, showing a synergistic therapeutic effect
    .

    At the same time, SP@Curcumin also eliminates the production of reactive oxygen species (ROS) in normal cells, reduces the DNA damage it induces, and protects normal intestinal tissues during radiotherapy
    .

    In addition to its application in cancer treatment, the research team also demonstrated the anti-inflammatory ability of SP@Curcumin in the intestine, which reduced the levels of pro-inflammatory cytokines and alleviated inflammation-related symptoms in colitis mice
    .

    In general, the study proposes a multifunctional drug delivery system SP@Curcumin, which can bypass physiological barriers and improve drug properties (such as oral bioavailability, biodegradation, and biocompatibility).
    The treatment also showed excellent anti-tumor and anti-inflammatory effects

    .

    The Second Affiliated Hospital of Zhejiang University School of Medicine/Institute of Translational Medicine Doctoral student Zhong Danni, PhD student Zhang Dongxiao, and the Harvard Medical School Brigham and Women's Hospital Chen Wei are the co-first authors.
    The Second Affiliated Hospital of Zhejiang University School of Medicine/Institute of Translational Medicine Zhou Min and Tao Wei from Harvard Medical School Brigham and Women's Hospital are the co-corresponding authors

    .

    Link to the paper: https:// is open for reprinting, welcome to forward to the circle of friends and WeChat groups 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.